Search
Icosabutate
go.drugbank.com/drugs/DB12990InvestigationalIcosabutate is under investigation in clinical trial NCT02373176 ([14C] Icosabutate -A Phase I Absorption, Metabolism and Excretion Study).
Izencitinib
go.drugbank.com/drugs/DB16660InvestigationalIzencitinib is under investigation in clinical trial NCT03920254 (TD-1473 Long-term Safety (LTS) Ulcerative Colitis (UC) Study).
Ibezapolstat
go.drugbank.com/drugs/DB16189InvestigationalIbezapolstat is under investigation in clinical trial NCT04247542 (ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection).
Agerafenib
go.drugbank.com/drugs/DB15068InvestigationalAgerafenib is under investigation in clinical trial NCT03052569 (Expanded Access to RXDX-105 for Cancers With RET Alterations).
Ravidasvir
go.drugbank.com/drugs/DB15652InvestigationalRavidasvir is under investigation in clinical trial NCT02961426 (Sofosbuvir Plus Ravidasvir for the Treatment of HCV Chronic Infection).
Allocetra
go.drugbank.com/drugs/DB16424InvestigationalWith infusion, the body's macrophages and dendritic cells can feed on these early apoptotic Allocetra cells and thus result in the macrophages and dendritic cells releasing fewer cytokine alert signals … so that the immune system is rebalanced back to normal -- averting a cytokine storm.
Cirtuvivint
go.drugbank.com/drugs/DB17269InvestigationalCirtuvivint is a first-in-class CDC-like kinase (CLK) inhibitor.
Synonyms: 4-pyridinecarboxamide, 2-(4-methyl-1-piperazinyl)-n-(6-(1-methyl-1h-pyrazol-4-yl)-3-isoquinolinyl)-Freneslerbart
go.drugbank.com/drugs/DB19080InvestigationalFreneslerbart is under investigation in clinical trial NCT04981717 (A Study to Examine the Efficacy and Safety of Anti-fel D 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic
beta-Alanine
go.drugbank.com/drugs/DB03107Investigationalbeta-Alanine is an amino acid formed in vivo by the degradation of [dihydrouracil] and [carnosine].
Navocaftor
go.drugbank.com/drugs/DB19039InvestigationalNavocaftor is under investigation in clinical trial NCT04853368 (Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/navocaftor/abbv-119 or Galicaftor/navocaftor … /abbv-576 Combination Therapies in Adult Participants With Cystic Fibrosis).